Loading stock data…
JSPR
$0.99+0.06 (+5.97%)
After Hours$0.99+0.00 (+0.00%)· Last close May 4
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jasper Therapeutics, Inc. in the Healthcare sector is trading at $0.97. The stock is currently near its 52-week low of $0.62, remaining 48.6% below its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why JSPR maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.99
Potential Upside
5%
Whystock Fair Value$1.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to b...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1826.09%
Volume
Today's trading volume
225,743
Recent News
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperform rating. Evercore ISI said the adjustment reflects updates across its small-to-mid cap biotechnology coverage as […]
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term […]
Jasper Therapeutics reports updated data from briquilimab studies
Jasper Therapeutics (JSPR) is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label extension study in CSU and CIndU. Treatment with briquilimab resulted in rapid disease control in the additional participants enrolled in the 240mg / 180mg Q8W cohort in the BEACON study, with 83% of participants achieving a complete response by week 3 after the initial 240mg dose, and 67% reportin
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Positive Signs As Multiple Insiders Buy Jasper Therapeutics Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...